Sanofi Wins FDA Approval for Infilbray to Address Neurological Symptoms of Gaucher Disease
Key Points
- FDA approved Infilbray (venglustat), the first U.S. medicine specifically for neurological manifestations of Type 3 Gaucher disease in patients weighing at least 15 kg
- Phase 3 LEAP2MONO showed statistically significant neurological improvements versus imiglucerase (p=0.0137) over 52 weeks
- Once-daily oral glucosylceramide synthase inhibitor crosses the blood-brain barrier to reduce glycosphingolipid accumulation in the central nervous system
Sanofi has received FDA approval for Infilbray (venglustat), an oral therapy for the treatment of neurological manifestations of Type 3 Gaucher disease (GD3) in adults and pediatric patients weighing at least 15 kg. The approval marks the first time a medicine has been authorized in the U.S. specifically to address the neurological complications associated with this rare inherited disorder.
Infilbray is a once-daily glucosylceramide synthase inhibitor (GCSi) designed to cross the blood-brain barrier. By targeting the accumulation of glycosphingolipids (GSLs) in the central nervous system (CNS), the therapy is intended to address neurological complications that have historically remained difficult to treat. By inhibiting the production of GSLs, the therapy is intended to reduce their abnormal accumulation and address the underlying disease processes associated with Type 3 Gaucher disease.
The FDA decision was supported by results from the Phase 3 LEAP2MONO trial (NCT05222906), which found that Infilbray demonstrated statistically significant improvements in neurological outcomes compared with imiglucerase, an established enzyme replacement therapy (ERT). A prespecified global analysis of multiple neurological endpoints showed superiority for Infilbray, with a p-value of 0.0137.
The 52-week study evaluated changes in motor and cognitive function, including measurements using the modified Scale for the Assessment and Rating of Ataxia (mSARA) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). Patients receiving Infilbray demonstrated improvements in neurological manifestations associated with cognitive impairment, coordination and balance.
Type 3 Gaucher disease is a chronic neuronopathic form of the disorder characterized by progressive neurological and systemic complications. Although ERT has helped manage systemic disease manifestations, including enlargement of the liver and spleen and certain blood abnormalities, existing treatments have not adequately addressed the effects of the disease on the CNS.
Manuela Buxo, Executive Vice President and Global Head of Specialty Care at Sanofi, says the approval represents an important addition to the company’s rare disease portfolio and reflects its efforts to address unmet medical needs.
Dr. Pramod Mistry, Director of the Yale Lysosomal Disease Center and Gaucher Disease Treatment Center, highlights the significance of the decision, noting that while systemic manifestations of GD3 have been manageable with existing therapies, neurological complications have remained beyond their reach.
The LEAP2MONO trial enrolled 43 adults and pediatric patients aged 12 years and older who had received ERT for at least three years and achieved treatment goals for their systemic disease manifestations. Participants were randomized to receive either once-daily oral Infilbray with placebo infusions or intravenous imiglucerase every two weeks with placebo tablets.
The trial’s primary endpoint combined changes in motor and cognitive function from baseline through Week 52. Secondary assessments included spleen and liver volume, hemoglobin levels, platelet counts, and biomarkers in cerebrospinal fluid and plasma. An open-label extension of the study is ongoing, with additional findings expected at a later date.
Sanofi reported several adverse reactions during the primary analysis period among patients receiving Infilbray (n=21), compared with those receiving imiglucerase (n=22). These included diarrhea (14% versus 0%), splenomegaly (14% versus 0%), nausea (14% versus 5%), depression (10% versus 0%), gastroenteritis (10% versus 0%), and vomiting (10% versus 5%).
Infilbray previously received FDA breakthrough therapy, rare pediatric disease, and fast-track designations. It also holds orphan drug designation in the U.S., European Union, and Japan. Beyond the U.S. approval, the therapy remains under regulatory review for GD3 in the EU, Japan, and other markets. Sanofi plans to pursue additional regulatory submissions in 2026 and 2027.
Visit www.sanofi.com for more information.
Total Page Views: 5

















